natgillin/translations-raw huggingface dataset:
estimating the fractional concentration of the clinically-relevant DNA in the biological sample based on the comparisons involving the first value and the one or more second values. The method of claim 3, wherein the first calibration data points and the second calibration data points are points on a multidimensional curve and the comparison includes identifying the multidimensional point having coordinates corresponding to the first value and the one or more second values. 
Metoda prema patentnom zahtjevu 3, naznačena time, što: prva točka podataka za kalibraciju određuje frakcionalnu koncentraciju fetalne DNK koja odgovara kalibracijskoj vrijednosti prvog parametra; jedna ili više drugih točaka podataka za kalibraciju određuje frakcionalnu koncentraciju fetalne DNK koja odgovara jednoj ili više kalibracijskih vrijednosti jednog ili više drugih parametara; i prva točka podataka za kalibraciju i druge točke podataka za kalibraciju su točke na višedimenzionalnoj krivulji te usporedba uključuje identifikaciju višedimenzionalne točke s koordinatama koje odgovaraju prvoj vrijednosti i jednoj ili više drugih vrijednosti.
A compound according to claim 36 wherein R4 is hydrogen, methyl or ethyl. 
Spoj u skladu s patentnim zahtjevom 36, naznačen time što R4 je vodik, metil ili etil.
The expansion joint according to any one of claims 8 to 11, wherein the second upper (6) and lower (17) corrugated plates are secured to one another. 
Kompenzacijski spoj prema zahtjevu 14, naznačen time da su druge gornje (6) i donje valovite ploče (17) međusobno pričvršćene preko veznog elementa (8).
The electrolysis process according to claim 6 or 7, characterized in that Al2O3 is quantitatively supplied in the electrolysis process. 
Proces elektrolize u skladu sa patentnim zahtjevom 6 ili 7, naznačen tima da AbO; je kvantitativno isporučen u procesu elektrolize.
Compounds of general formula (I) in which 
PATENTNI ZAHTJEVI Spojevi opće formule (I)
ST1899 and ST2472 were separately incubated with the hepatic microsomes. 
ST1899 1 ST2472 odijeljeno su inkubirani s jetrenim mikrosomima.
is a single bond when R2 is present, or --- is a double bond when R2 is absent; and Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, hydroxy, thioxy, cyano, nitro, C1-4 haloalkyl, amino, C1-4 alkylamino, C2-8 dialkylamino, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-5 cycloalkyl, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, C1-4 haloalkylthio, C1-4 haloalkylsulfinyl and C1-4 haloalkylsulfonyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
je jednostruka veza u slučaju kada je R2 prisutan ili je dvostruka veza u slučaju kada je R» odsutan; te Prsten A je 5-člani karbociklički prsten ili 5-člani heterociklički prsten po izboru supstituiran sa do 4 supstituenda izabrana iz skupine koju čine halogen, hidroksi, tioksi, cijano, nitro, Ci4 haloalkil, amino, C;.4 alkilamino, C2g dialkilamino, C;.4 alkil, C,4 alkoksi, C2., alkenil, C, alkinil, C;.5 cikloalkil, C;,.y haloalkoksi, Ci.a alkiltio, C,.4 alkilsulfinil, C;.4 alkilsulfonil, C;.4 haloalkiltio, C;.4 haloalkilsulfinil i C,.4 haloalkilsulfonil; ili njihove farmaceutski prihvatljive soli, solvate ili hidrate.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a salt thereof and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili njenu sol 1 farmaceutski prihvatljiv nosač.
With this only partial filling, the filling medium can be removed easier from the groove structures 4 after the mechanical machining of the composite structure. 
S tim, samo djelomičnim punjenjem, punilo se može odstraniti lakše iz brazdastih struktura 4 nakon mehaničke strojne obrade kompozitne strukture.
A composition comprising multimers of dimers of the polypeptides of claim 1 or 2, wherein the multimers are present at a percentage of at least about 45%, or at least about 55%, or at least about 65%, or at least about 70%, or at least about 73% of the total composition. 
3. > Sastav, naznačen time, da obuhvaća multimere dimera od polipeptida iz zahtjeva 1 ili 2, pri čemu su multimeri prisutni u postotku od najmanje oko 45%, ili najmanje oko 55%, ili najmanje oko 65%, ili najmanje oko 70%, ili najmanje oko 73% od ukupnog sastava.
The antibody or antigen binding portion thereof of claim 1, wherein the EGF-like ligand is betacellulin. 
Protutijelo ili njegov dio za vezanje na antigen u skladu s patentnim zahtjevom 1, naznačeno time, da je EGF-sličan ligand jeste betacelulin.
Dairy animals such as cattle, sheep and goats are thus preferred hosts. 
Životinje koje proizvode mlijeko poput goveda, ovaca i koza su, prema tome, poželjni domaćini.
permanently magnetizing the unmagnetized body of permanent-magnetic material of step b) in a direction substantially perpendicular to the at least one flat or cylindrically curved surface. 
€) permanentno magnetiziranje graviranog tijela iz koraka b) u smjeru koji je u znatnoj mjeri okomit na površinu koja nosi oznaku.
is a direct bond or O; 
X' je izravna veza ili O;
Embodiment 16 A kit according to any one of embodiments 14 and 15, further comprising a brush for applying the radiation curable gel nail coating composition. 
Komercijalni komplet prema patentnom zahtjevu 13, koji dalje sadrži četkicu za nanošenje pripravaka u vidu gellaka za nokte za čije sušenje se korisiti zračenje.
A system according to any of paragraphs a) to i) wherein the base plate units 20 show extending grooves 21 b to guide and fix a clamp or other fixing device 40 and/or the insulation material 50 . 
Sustav temeljem bilo kojeg od zahtjeva 1 do 4 pri čemu su izrađena rebra na jedinici bazne ploče (20), poželjno transverzalna (22a) i/ili periferna (22b).
That is, the present invention relates to: use of the compound represented by the formula (I-a) or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for pain; 
PATENTNI ZAHTJEVI Spoj, naznačen time, da je predstavljen sljedećom formulom (1-b) ili njegova farmaceutski prihvatljiva sol koji se upotrebljava za liječenje bolova odabranih od pva bolova 1 fibromialgije:
Vehicle according to claim 17 or 18, characterized in that it is a rail vehicle having a low floor section, said main tank being located in an underfloor section (1.3) of said low floor section. 
Vozilo u skladu s patentnim zahtjevom 15 ili 16, naznačeno time što se radi o vozilu na tračnicama koje ima predio s niskim podom, pri čemu je navedeni glavni spremnik smješten u predjelu ispod poda (1.3) navedenog predjela s niskim podom.
A therapeutic agent or prophylactic agent for cognitive disorders containing, as an active ingredient, a peptide that includes a sequence of at least 8 contiguous amino acids from the amino acid sequence consisting of amino acid numbers 410-421 of SEQ ID NO: 1, at least one of the amino acid residues in the peptide being phosphorylated. 
Terapeutski agens ili profilaktički agens za uporabu prema bilo kojem od zahtjeva 1 do 7, pri čemu je vezanje antitijela na tau protein fosforiliran na ostatku aminokiseline koji odgovara Ser413 od SEQ ID NO: 1 barem 30 puta, ili barem 100 puta jače od vezanja na tau protein koji nije bio fosforiliran na spomenutom Ser413.
A pharmaceutical composition according to claim 1, wherein the carrier matrix is d-alpha-tocopheryl polyethylene glycol 1000 succinate or Lauroyl Macrogol-32 Glycerides. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time da je matrica nosača d-alfa-tokoferil polietilen glikol 1000 sukcinat ili Lauroil Makrogol-32 gliceridi.
Cells are washed with PBS and resuspended in stimulation buffer to a concentration of 0.4×106/mL and added to the assay plate (10 uL/well). 
Stanice su isprane s PBS-om i ponovno suspendirane u puferu za stimulaciju na koncentraciju od 0,4 x 10*/ml i dodane su u pokusnu pločicu (10 ul/jamici).
Typically lozenges are not smaller than 300-400 mg and are not larger than approximately 1.5 g, approximately 1.75 g or approximately 2 g. 
Tipično, tablete nisu manje od 300-400mg 1 nisu veće od približno 1.5 g, približno 1.75 g ili približno 2 g.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least one mRNA molecule encoding a peptide or polypeptide, wherein the at least one mRNA molecule is encapsulated in a liposome having a size of less than 100 nm, wherein said liposome comprises one or more cationic lipid(s), one or more non-cationic lipid(s), and one or more PEG-modified lipid(s). 
nosač transfera i najmanje jednu molekulu iRNK koja kodira navedeni protein, nosač transfera koji sadrži jedan ili više kationskih lipida, jedan ili više nekationskih lipida i jedan ili više lipida modificiranih s PEG, pri čemu je nosač transfera liposom, a veličina nosača transfera je manja od 100 nm, i pri čemu se farmaceutski pripravak poželjno nakon primjene subjektu distribuira u stanice jetre, a kodirani protein se eksprimira u stanicama jetre subjekta.
After 40 min, 1-chloro-3-iodopropane (2.7 mL, 25 mmol) was added at once, stirred at −78° C. for 1 h and 4 h room temperature. 
Poslije 40 min, 1-kloro-3-jodopropan (2.7 mL, 25 mmol) je dodan odjednom, miješan na -78*C 1 sat i 4 sata na sobnoj temperaturi.
In addition the coated fruit was firmer to the touch and the internal flesh was not translucent and displayed no internal brown spots, which is indicative of loss of shelf life vs. the control that was translucent and had brown spots in one half of the samples. 
Pored toga što je obloženo voće bilo čvršće na dodir, unutrašnji mesnati dio nije bio proziran i nije bilo unutrašnjih smeđih HR P20070056 T3 točaka, što ukazuje na gubitak roka upotrebe u odnosu na kontrolu koja je bila prozirna i imala je smeđe točke kod jedne polovine uzoraka.
The process of any of the previous claims, wherein the obtained remineralized water has a calcium concentration as calcium carbonate from 15 to 200 mg/L, preferably from 30 to 150 mg/L, and most preferably from 100 to 125 mg/L, or from 15 to 100 mg/L, preferably from 20 to 80 mg/L, and most preferably from 40 to 60 mg/L. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da dobivena remineralizirana voda ima koncentraciju kalcija kao kalcijevog karbonata od 15 do 200 mg/L, poželjno od 30 do 150 mg/L, i najpoželjnije od 100 do 125 mg/L, ili od 15 do 100 mg/L, poželjno od 20 do 80 mg/L, i najpoželjnije od 40 do 60 mg/L.
A particularly preferred embodiment employs two consecutive disk stack centrifuges to centrifuge the mixture of the fish oil and the polar solvent, or optionally the mixture of the polar fraction, the polar solvent and the fish oil. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, pri čemu korak razdvajanja obuhvaća centrifugiranje smjese polarne frakcije, polarnog otapala i ribljeg ulja zbog razdvajanja koncentrirane polarne frakcije od lipidne frakcije.
This known machine can present three separate boiler sets. 
Ovaj poznati stroj može sadržavati tri odvojene grupe kotlova.
The reaction is stirred at room temperature for 2 hours under orbital stirring. 
Reakcijsku smjesu miješa se 2 sata na sobnoj temperaturi orbitalnim miješalom.
By such computing procedure densities within different distance zones of the map can be efficiently and precisely determined. In an implementation form of the method the first distance zone and the second distance zone are non-overlapping sections of the user density map. 
Postupak (100) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su zona prve udaljenosti (401a) i zona druge udaljenosti (401c) nepreklapajuće zone udaljenosti na karti gustoće korisnika (400).
The compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl, 1,1-difluoroethyl, trifluoromethoxy, difluoromethoxy, and 1,1,2,2-tetrafluoroethoxy, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R2 se bira iz skupine koju čine vodik, fluor, klor, cijano, trifluormetil, 1,1-difluoretil, trifluormetoksi, difluormetoksi, te 1,1,2,2-tetrafluoretoksi, ili njegova farmaceutski prihvatljiva sol.
The method of claim 7, wherein the cellulose ether is selected from the group of cellulose ethers consisting of hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cationic cellulose, carboxymethyl cellulose and combinations thereof. 
Zidna gips ploča prema bilo kojem od prethodnih zahtjeva, naznačena time, da organsko-anorganski kompozit nadalje obuhvaća celulozni eter odabran iz skupine koju čine hidroksipropilmetil-celuloza, metil-celuloza, hidroksietilmetil-celuloza, hidroksietil-celuloza, hidroksipropil-celuloza, kationska celuloza, karboksimetil-celuloza i njihove kombinacije.
The air inversion and steam cure apparatus of claim 17, wherein the compressible material (46) is silicone rubber and the absorbent layer is felt. 
Uređaj za sanaciju zračnom inverzijom i parom prema patentnom zahtjevu 17, naznačen time da je kompresibilni materijal (46) silikonska guma, a apsorpcijski sloj je file.
HO-R1 (IV) wherein R1 is defined above, in the presence of a base to allow esterification, 
HO-R (IV) gdje je R određen gore, u prisutnosti baze da se omogući esterifikacija, (2) reagiranje spoja formule (II):
Next, the phases are separated. 
A t do da FI ni, na
The term “methylene,” as used herein, refers to a —CH2— group. 
Termin "metilen", kao što se ovdje upotrebljava, odnosi se na skupinu.
As two independent thermoblocks 3, 4 are connected respectively with a brewing chamber 5, 6, two brewed beverages can be obtained at the beverage outlet 7, 8 at the same time. 
Kako su dva neovisna termobloka 3 i 4 odgovarajuće povezana s komorama za kuhanje 5 i 6, na izlazima za napitke 71 8 može se istodobno dobiti dva kuhana napitka.
The flask was plugged and kept under stirring at room temperature for 2 days. 
Tikvica je začepljena 1 održavana uz miješanje pri sobnoj temperaturi 2 dana.
Soluble, non selective, non digestible polysaccharides such as guar gum, arabic gum, carboxycellulose and pectin suppress these effects. 
Topljivi, neselektivni, neprobavljivi polisaharidi, npr. guarova guma, arapska guma, karboksiceluloza i pektin potiskuju te učinke.
We emphasize, that a number of clinical trials had been run in order to prove the intrinsic analgesic effect of dextromethorphan. 
Mi naglašavamo, da su brojni klinički pokusi bili provedeni sa ciljem da se provjeri svojstveni analgetski učinak dekstrometorfana.
The compound of claim 25 wherein G4 is H. 
Spoj iz zahtjeva 25 gdje je G4 H.
A compound of any one of claim 1 to 22, wherein R2 or R3 comprises at least one cyclic moiety. 
Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 22, naznačen time, što R2 ili R3 sadrži najmanje jednu cikličnu grupu.
▪ an aryl group or aryl-(C1-C7)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or 
arilnu skupinu ili aril(C,-C7)alkilnu skupinu supstituiranu s jednom ili više skupina odabranih od OH i NRoRy9 skupina, s tim da Ry i Ryo jesu kao što je definirano u patentnom zahtjevu 1, ili .
The formulation of claim 8, wherein the zinc chelator is ethylenediaminetetraacetic acid (EDTA). 
Formulacija prema zahtjevu 5, naznačena time da je kelator cinka etilendiamintetraoctena kiselina (EDTA).
Column regeneration was carried out at the end of the elution gradient. 
Regeneracija kolone je bila provedena na kraju elucijskog gradijenta.
4 shows a side view of a mouthpiece cap which can be incorporated into an inhaler according to a preferred form of the present invention, the cap is shown from the side and the cap is in the closed position in which it fits over the mouthpiece in order to occlude it; and 
Slika 4 je bočni pogled na zatvarač kljuna koji se može ugraditi u inhalator sukladno poželjnoj realizaciji ovog izuma, a zatvarač je prikazan bočno i u zatvorenom je položaju u kojem je postavljen preko kljuna i potpuno ga okružuje; te
The EPA and DHA ethyl ester assay is preferably higher than 85% by weight. 
Udio EPA i DHA Â«til estera je poželjno viši od 85 % po masi.
A method according to any one of claims 1 - 6, characterized in that the sheet lid (2) is punched in advance of closing a cup and is thus adapted in size and shape to the opening of the cup. 
Postupak prema bilo kojem od Zahtjeva 1 do 6, naznačen time, što se ravni poklopac (2) dobiva prosijecanjem koje prethodi zatvaranju čaše te je, stoga, svojom veličinom i oblikom prilagođen otvoru čaše.
The chimeric polypeptide of any one of items 1 to 5, having at least 80%, preferably 90%, amino acid sequence identity with the polypeptide of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 15, and having essentially the same biological activity as the corresponding polypeptide of SEQ NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 15. 
3. Kimerni polipeptid u skladu s patentnim zahtjevom 1 ili 2, naznačen time što mu je aminokiselinski slijed najmanje 80%, po mogućnosti 90%, identičan s polipeptidom sa SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 ili SEQ ID NO: 15.
Often the second compound is produce by reacting a compound of the formula (R5NH2), wherein: R5 is hydrogen, or unsubstituted or substituted C1-C20 alkyl, with a compound of formula HX'. 
(1ii) R7 je vodik, nesupstituirani ili supstituirani C,-C29-alkil, ili nesupstituirani ili supstituirani aril i (1V) Ra je vodik, nesupstituirani ili supstituirani Ci-C2o-alkil, ili nesupstituirani ili supstituirani aril;
A method in accordance with claim 1 or claim 2, wherein the condition related to diabetes is selected from the group consisting of hyperglycemia, impaired glucose tolerance, insulin resistance, pancreatic beta-cell insufficiency, enteroendocrine cell insufficiency, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic coronary artery disease, diabetic cerebrovascular disease, diabetic peripheral vascular disease, metabolic syndrome, hyperlipidemia, atherosclerosis, stroke, hypertension, and obesity. 
Pripravak u skladu sa zahtjevom 35, naznačen time, da služi za liječenje ili prevenciju stanja povezanih s dijabetesom izabranih iz skupine koju čine hiperglikemija, smanjena tolerancija glukoze, inzulinska rezistencija, insuficijencija beta-stanica pankreasa, insuficijencija enteroendokrinih stanica, glikozurija, matabolička acidoza, katarakte, dijabetička nefropatija, dijabetička neuropatija, dijabetička retinopatija, dijabetičko oboljenje srčanih arterija, dijabetička cerebrovaskularna bolest, dijabetička periferna vaskularna bolest, metabolički sindrom, hiperlipidemija, ateroskleroza, udar, hipertenzija i debljina.
The latter, during the rotation of the carrousel, comes in contact with a cam (not shown), appropriately shaped and fixed, to synchronise the movement of the third suction cup 5 with the rotation of the carrousel. 
Ovaj posljednji za vrijeme rotiranja rotirajućeg stroja dolazi u kontakt s ekscentrom (nije prikazan), koji je na odgovarajući način oblikovan i učvršćen, da bi sinkronizirao pomicanje treće usisne čašice 5 s rotiranjem rotirajućeg stroja.
The process according to claims 1 or 2, wherein said aqueous stream (iv) is fed to catalytic steam reforming. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, naznačen time što se navedenu struju vode (iv) pušta na katalitičko reformiranje vodenom parom.
a first, heterologous polynucleotide coding for and expressing a Newcastle Disease Virus F (NDV-F) antigen, wherein the NDV-F antigen has at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 33, 35, or 37; and 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da sekvenca proteina NDV-F ima najmanje 90% identiteta sekvence prema sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54.
The antibody, fragment, or composition for use according to claim 16, wherein the method further comprises administering to the subject one or more additional therapeutic agents selected from the group consisting of an inhibitor of HMG-CoA reductase, niacin, a fibrate, 22-hydroxycholesterol, ezetimibe plus simvastatin, a statin with a bile resin, niacin plus a statin, niacin plus an omega-3-fatty acid ethyl ester, a statin, an anti-hANGPTL4 antibody and an anti-PCSK9 antibody, optionally wherein the antibody or fragment thereof and the one or more additional therapeutic agents are administered concurrently or sequentially. 
Antitijelo, fragment ili pripravak za primjenu prema patentnom zahtjevu 11 ili 12, naznačen time, što se način dodatno sastoji od primjene kod ispitanika jednog ili više dodatnih terapijskih sredstava odabranih iz skupine koja se sastoji od inhibitora HMG-CoA reduktaze, niacina, fibrata, 22-hidroksikolesterola, ezetimiba plus simvastatina, statina sa žučnom smolom, niacina plus statina, niacina plus etilnog estera omega-3 masne kiseline, statina, anti-hANGPTL4 antitijela i anti-PCSK9 antitijela. Antitijelo, fragment ili pripravak za primjenu prema patentnom zahtjevu 13, naznačen time, što se antitijelo ili njegov fragment i jedno ili više terapijskih sredstava primjenjuju istovremeno ili sekvencijalno.
R105, R106 and R107 are independently selected from hydrogen, halogen, optionally substituted C1-C24 alkyl, optionally substituted C2-C24 alkenyl, optionally substituted C2-C24 alkynyl, optionally substituted C3-C24 cycloalkyl, optionally substituted C1-C24 alkoxy, optionally substituted C1-C24 alkylamino and optionally substituted C1-C24 aryl; 
, R106 i R107 su nezavisno izabrani od vodika, halogena, izborno supstituiranog C1-C24 alkila, izborno supstituiranog C2-C24 alkenila, izborno supstituiranog C2-C24 alkinila, izborno supstituiranog C3-C24 cikloalkila, izborno supstituiranog C1-C24 alkoksi, izborno supstituiranog C1-C24 alkilamino i izborno supstituiranog C1-C24 arila;
is selected from the group consisting of isopropenyl, Z-2-propen-3-yl and (+)-vinyl; 
R* je izabran iz grupe koja se sastoji od izopropenil, Z-2-propen-3-il i (-*-)-vinil;
The resulting solid is dissolved in water (30 ml) and acidified to pH 2-3 using concentrated HCl. 
Dobivenu krutu tvar se otopi u vodi (30 ml) i zakiseli na pH 2-3 upotrebom koncentrirane HC1.
Feeding assembly according to claim 1 or 2, wherein the base of the teat is provided with a flange, preferably made of a resilient material, the flange of the teat extending in an outward direction, and the mounting ring is provided with a flange for engaging the flange of the teat and clamping the flange of the teat onto the cup holder, preferably onto the flange of the single serve cup held in the holder, in an assembled state of the feeding bottle, and/or the dome and the spout of the teat, and preferably the flange of the teat, are integral, and the teat is made of a pliant material, preferably of a silicone material, and/or the mounting ring and the cup holder are provided with screw thread, such that the mounting ring can be screwed onto the cup holder for securing the teat onto the cup holder. 
Sustav za hranjenje u skladu s patentnim zahtjevom 1 ili 2, naznačen time što podnožje dude ima prirubnicu, po mogućnosti načinjenu od elastičnog materijala, gdje se prirubnica dude pruža prema van, a montažni prsten ima prirubnicu za međudjelovanje s prirubnicom dude i pritezanje prirubnice dude na držač šalice, po mogućnosti na prirubnicu šalice s jednim obrokom koju drži držač, u sklopljenom stanju bočice za bebe, i/ili kupola 1 kljun dude, te po mogućnosti prirubnica dude, su integralni, a duda je načinjena od savitljivog materijala, po mogućnosti od silikonskog materijala, ifili montažni prsten 1 držač šalice imaju vijčani navoj, tako da se montažni prsten može naviti na držač šalice radi osiguravanja dude na držač šalice. 4.